BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Volz T, Allweiss L, Ḿbarek MB, Warlich M, Lohse AW, Pollok JM, Alexandrov A, Urban S, Petersen J, Lütgehetmann M, Dandri M. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. Journal of Hepatology 2013;58:861-7. [DOI: 10.1016/j.jhep.2012.12.008] [Cited by in Crossref: 211] [Cited by in F6Publishing: 199] [Article Influence: 23.4] [Reference Citation Analysis]
Number Citing Articles
1 Bitton Alaluf M, Shlomai A. New therapies for chronic hepatitis B. Liver Int 2016;36:775-82. [DOI: 10.1111/liv.13086] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
2 van den Berg F, Limani SW, Mnyandu N, Maepa MB, Ely A, Arbuthnot P. Advances with RNAi-Based Therapy for Hepatitis B Virus Infection. Viruses 2020;12:E851. [PMID: 32759756 DOI: 10.3390/v12080851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
3 Colpitts CC, Verrier ER, Baumert TF. Targeting Viral Entry for Treatment of Hepatitis B and C Virus Infections. ACS Infect Dis 2015;1:420-7. [PMID: 27617925 DOI: 10.1021/acsinfecdis.5b00039] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
4 Revill P, Testoni B, Locarnini S, Zoulim F. Global strategies are required to cure and eliminate HBV infection. Nat Rev Gastroenterol Hepatol. 2016;13:239-248. [PMID: 26907881 DOI: 10.1038/nrgastro.2016.7] [Cited by in Crossref: 96] [Cited by in F6Publishing: 92] [Article Influence: 16.0] [Reference Citation Analysis]
5 El Bouzidi K, Elamin W, Kranzer K, Irish DN, Ferns B, Kennedy P, Rosenberg W, Dusheiko G, Sabin CA, Smith BC, Nastouli E. Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London. J Clin Virol. 2015;66:33-37. [PMID: 25866333 DOI: 10.1016/j.jcv.2015.02.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
6 Wing PA, Davenne T, Wettengel J, Lai AG, Zhuang X, Chakraborty A, D'Arienzo V, Kramer C, Ko C, Harris JM, Schreiner S, Higgs M, Roessler S, Parish JL, Protzer U, Balfe P, Rehwinkel J, McKeating JA. A dual role for SAMHD1 in regulating HBV cccDNA and RT-dependent particle genesis. Life Sci Alliance. 2019;2. [PMID: 30918010 DOI: 10.26508/lsa.201900355] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
7 Wu L, Xu W, Li X, Liu Y, Wang L, Zhu S, Yang F, Xie C, Peng L. The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment. Front Pharmacol 2021;12:616858. [PMID: 33716744 DOI: 10.3389/fphar.2021.616858] [Reference Citation Analysis]
8 Gill US, Kennedy PT. Chronic hepatitis B virus in young adults: the need for new approaches to management. Expert Rev Anti Infect Ther 2014;12:1045-53. [PMID: 25052517 DOI: 10.1586/14787210.2014.940899] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
9 Casillas R, Tabernero D, Gregori J, Belmonte I, Cortese MF, González C, Riveiro-Barciela M, López RM, Quer J, Esteban R, Buti M, Rodríguez-Frías F. Analysis of hepatitis B virus preS1 variability and prevalence of the rs2296651 polymorphism in a Spanish population. World J Gastroenterol 2018; 24(6): 680-692 [PMID: 29456407 DOI: 10.3748/wjg.v24.i6.680] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Leowattana W, Leowattana T. Chronic hepatitis B: New potential therapeutic drugs target. World J Virol 2022; 11(1): 57-72 [DOI: 10.5501/wjv.v11.i1.57] [Reference Citation Analysis]
11 Winer BY, Huang TS, Pludwinski E, Heller B, Wojcik F, Lipkowitz GE, Parekh A, Cho C, Shrirao A, Muir TW, Novik E, Ploss A. Long-term hepatitis B infection in a scalable hepatic co-culture system. Nat Commun 2017;8:125. [PMID: 28743900 DOI: 10.1038/s41467-017-00200-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
12 Fauzyah Y, Ono C, Torii S, Anzai I, Suzuki R, Izumi T, Morioka Y, Maeda Y, Okamoto T, Fukuhara T, Matsuura Y. Ponesimod suppresses hepatitis B virus infection by inhibiting endosome maturation. Antiviral Res 2021;186:104999. [PMID: 33346055 DOI: 10.1016/j.antiviral.2020.104999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Takyar V, Surana P, Kleiner DE, Wilkins K, Hoofnagle JH, Liang TJ, Heller T, Koh C. Noninvasive markers for staging fibrosis in chronic delta hepatitis. Aliment Pharmacol Ther. 2017;45:127-138. [PMID: 27813124 DOI: 10.1111/apt.13834] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
14 Wang XY, Chen HS. Emerging antivirals for the treatment of hepatitis B. World J Gastroenterol 2014; 20(24): 7707-7717 [PMID: 24976708 DOI: 10.3748/wjg.v20.i24.7707] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
15 Jia H, Rai D, Zhan P, Chen X, Jiang X, Liu X. Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview. Future Med Chem. 2015;7:587-607. [PMID: 25921400 DOI: 10.4155/fmc.15.19] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
16 Düzgüneş N, Fernandez-Fuentes N, Konopka K. Inhibition of Viral Membrane Fusion by Peptides and Approaches to Peptide Design. Pathogens 2021;10:1599. [PMID: 34959554 DOI: 10.3390/pathogens10121599] [Reference Citation Analysis]
17 Foster JR, Lund G, Sapelnikova S, Tyrrell DL, Kneteman NM. Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies. Xenobiotica 2014;44:109-22. [DOI: 10.3109/00498254.2013.867553] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
18 Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, Lehr T, Lempp FA, Wedemeyer H, Haag M, Schwab M, Haefeli WE, Blank A, Urban S. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol. 2016;65:490-498. [PMID: 27132170 DOI: 10.1016/j.jhep.2016.04.016] [Cited by in Crossref: 190] [Cited by in F6Publishing: 166] [Article Influence: 31.7] [Reference Citation Analysis]
19 Tavanez JP, Caetano R, Branco C, Brito IM, Miragaia-Pereira A, Vassilevskaia T, Quina AS, Cunha C. Hepatitis delta virus interacts with splicing factor SF3B155 and alters pre-mRNA splicing of cell cycle control genes. FEBS J 2020;287:3719-32. [PMID: 32352217 DOI: 10.1111/febs.15352] [Reference Citation Analysis]
20 Soriano V, Aguilera A. Hepatitis Delta Enters a New Therapeutic Era. The Journal of Infectious Diseases 2018;217:1173-6. [DOI: 10.1093/infdis/jix658] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
21 Sa-Ngiamsuntorn K, Thongsri P, Pewkliang Y, Wongkajornsilp A, Kongsomboonchoke P, Suthivanich P, Borwornpinyo S, Hongeng S. An Immortalized Hepatocyte-like Cell Line (imHC) Accommodated Complete Viral Lifecycle, Viral Persistence Form, cccDNA and Eventual Spreading of a Clinically-Isolated HBV. Viruses 2019;11:E952. [PMID: 31623162 DOI: 10.3390/v11100952] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
22 Lee HM, Banini BA. Updates on Chronic HBV: Current Challenges and Future Goals. Curr Treat Options Gastro 2019;17:271-91. [DOI: 10.1007/s11938-019-00236-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
23 Loggi E, Vitale G, Conti F, Bernardi M, Andreone P. Chronic hepatitis B: Are we close to a cure? Dig Liver Dis. 2015;47:836-841. [PMID: 26138799 DOI: 10.1016/j.dld.2015.05.019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
24 Herrscher C, Roingeard P, Blanchard E. Hepatitis B Virus Entry into Cells. Cells 2020;9:E1486. [PMID: 32570893 DOI: 10.3390/cells9061486] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
25 Tao Y, Wu D, Zhou L, Chen E, Liu C, Tang X, Jiang W, Han N, Li H, Tang H. Present and Future Therapies for Chronic Hepatitis B. Adv Exp Med Biol. 2020;1179:137-186. [PMID: 31741336 DOI: 10.1007/978-981-13-9151-4_6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
26 Nakabori T, Hikita H, Murai K, Nozaki Y, Kai Y, Makino Y, Saito Y, Tanaka S, Wada H, Eguchi H, Takahashi T, Suemizu H, Sakamori R, Hiramatsu N, Tatsumi T, Takehara T. Sodium taurocholate cotransporting polypeptide inhibition efficiently blocks hepatitis B virus spread in mice with a humanized liver. Sci Rep 2016;6:27782. [PMID: 27278060 DOI: 10.1038/srep27782] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
27 Baltayiannis G, Karayiannis P. Treatment options beyond IFNα and NUCs for chronic HBV infection: expectations for tomorrow. J Viral Hepat 2014;21:753-61. [PMID: 25271858 DOI: 10.1111/jvh.12307] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
28 von Schaewen M, Hrebikova G, Ploss A. Generation of Human Liver Chimeric Mice for the Study of Human Hepatotropic Pathogens. Methods Mol Biol 2016;1438:79-101. [PMID: 27150085 DOI: 10.1007/978-1-4939-3661-8_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
29 Martinez MG, Testoni B, Zoulim F. Biological basis for functional cure of chronic hepatitis B. J Viral Hepat 2019;26:786-94. [DOI: 10.1111/jvh.13090] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
30 Lin C, Kao J. Perspectives and control of hepatitis B virus infection in Taiwan. Journal of the Formosan Medical Association 2015;114:901-9. [DOI: 10.1016/j.jfma.2015.06.003] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 7.0] [Reference Citation Analysis]
31 Zeisel MB, Baumert TF. Hepatitis B virus: is a cure possible? Expert Rev Clin Pharmacol 2016;9:1129-30. [PMID: 27347775 DOI: 10.1080/17512433.2016.1206466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Verrier ER, Colpitts CC, Bach C, Heydmann L, Weiss A, Renaud M, Durand SC, Habersetzer F, Durantel D, Abou-jaoudé G, López Ledesma MM, Felmlee DJ, Soumillon M, Croonenborghs T, Pochet N, Nassal M, Schuster C, Brino L, Sureau C, Zeisel MB, Baumert TF. A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses: VIRAL HEPATITIS. Hepatology 2016;63:35-48. [DOI: 10.1002/hep.28013] [Cited by in Crossref: 93] [Cited by in F6Publishing: 87] [Article Influence: 13.3] [Reference Citation Analysis]
33 Matsuda S, Maekawa S, Komiyama Y, Nakakuki N, Muraoka M, Suzuki Y, Sato M, Tatsumi A, Miura M, Amemiya F, Shindo H, Takano S, Fukasawa M, Yamaguchi T, Nakayama Y, Inoue T, Sato T, Yamashita A, Moriishi K, Enomoto N. Deep sequencing analysis of serum hepatitis B virus-RNA during nucleot(s)ide analogue therapy. Hepatol Res 2021;51:39-50. [PMID: 32961003 DOI: 10.1111/hepr.13574] [Reference Citation Analysis]
34 Ebert G, Pellegrini M. Cancer drugs for hepatitis B treatment: what do we know? Future Virology 2015;10:1025-8. [DOI: 10.2217/fvl.15.78] [Reference Citation Analysis]
35 Mohd-Ismail NK, Lim Z, Gunaratne J, Tan YJ. Mapping the Interactions of HBV cccDNA with Host Factors. Int J Mol Sci. 2019;20. [PMID: 31480501 DOI: 10.3390/ijms20174276] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
36 Billioud G, Kruse RL, Carrillo M, Whitten-Bauer C, Gao D, Kim A, Chen L, McCaleb ML, Crosby JR, Hamatake R, Hong Z, Garaigorta U, Swayze E, Bissig KD, Wieland S. In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides. J Hepatol. 2016;64:781-789. [PMID: 26658683 DOI: 10.1016/j.jhep.2015.11.032] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
37 Slijepcevic D, van de Graaf SF. Bile Acid Uptake Transporters as Targets for Therapy. Dig Dis 2017;35:251-8. [PMID: 28249291 DOI: 10.1159/000450983] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
38 Rybicka M, Bielawski KP. Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection. Microorganisms. 2020;8. [PMID: 32942584 DOI: 10.3390/microorganisms8091416] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
39 Appelman MD, Chakraborty A, Protzer U, McKeating JA, van de Graaf SF. N-Glycosylation of the Na+-Taurocholate Cotransporting Polypeptide (NTCP) Determines Its Trafficking and Stability and Is Required for Hepatitis B Virus Infection. PLoS One 2017;12:e0170419. [PMID: 28125599 DOI: 10.1371/journal.pone.0170419] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
40 Schreiner S, Nassal M. A Role for the Host DNA Damage Response in Hepatitis B Virus cccDNA Formation-and Beyond? Viruses 2017;9:E125. [PMID: 28531167 DOI: 10.3390/v9050125] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 9.6] [Reference Citation Analysis]
41 Chen PJ, Wu TC. One step closer to an experimental infection system for Hepatitis B Virus? --- the identification of sodium taurocholate cotransporting peptide as a viral receptor. Cell Biosci 2013;3:2. [PMID: 23311606 DOI: 10.1186/2045-3701-3-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
42 Sun D, Zhu L, Yao D, Chen L, Fu L, Ouyang L. Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives. European Journal of Medicinal Chemistry 2018;147:205-17. [DOI: 10.1016/j.ejmech.2018.02.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
43 Qu B, Brown RJP. Strategies to Inhibit Hepatitis B Virus at the Transcript Level. Viruses 2021;13:1327. [PMID: 34372533 DOI: 10.3390/v13071327] [Reference Citation Analysis]
44 Koumbi L. Current and future antiviral drug therapies of hepatitis B chronic infection. World J Hepatol 2015; 7(8): 1030-1040 [PMID: 26052392 DOI: 10.4254/wjh.v7.i8.1030] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
45 Tu T, Zehnder B, Qu B, Ni Y, Main N, Allweiss L, Dandri M, Shackel N, George J, Urban S. A novel method to precisely quantify hepatitis B virus covalently closed circular (ccc)DNA formation and maintenance. Antiviral Res 2020;181:104865. [PMID: 32726641 DOI: 10.1016/j.antiviral.2020.104865] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
46 Ito K, Okumura A, Takeuchi JS, Watashi K, Inoue R, Yamauchi T, Sakamoto K, Yamashita Y, Iguchi Y, Une M, Wakita T, Umezawa K, Yoneda M. Dual Agonist of Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo. Hepatology 2021;74:83-98. [PMID: 33434356 DOI: 10.1002/hep.31712] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Dawood A, Abdul Basit S, Jayaraj M, Gish RG. Drugs in Development for Hepatitis B. Drugs 2017;77:1263-80. [PMID: 28660478 DOI: 10.1007/s40265-017-0769-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
48 Goh B, Choi J, Kang JA, Park SG, Seo J, Kim TY. Development of a mass spectrometric screening assay for hepatitis B virus entry inhibitors. J Pharm Biomed Anal 2020;178:112959. [PMID: 31722821 DOI: 10.1016/j.jpba.2019.112959] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Drexler JF, Geipel A, König A, Corman VM, van Riel D, Leijten LM, Bremer CM, Rasche A, Cottontail VM, Maganga GD. Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes. Proc Natl Acad Sci USA. 2013;110:16151-16156. [PMID: 24043818 DOI: 10.1073/pnas.1308049110] [Cited by in Crossref: 118] [Cited by in F6Publishing: 109] [Article Influence: 13.1] [Reference Citation Analysis]
50 Eller C, Heydmann L, Colpitts CC, Verrier ER, Schuster C, Baumert TF. The functional role of sodium taurocholate cotransporting polypeptide NTCP in the life cycle of hepatitis B, C and D viruses. Cell Mol Life Sci. 2018;75:3895-3905. [PMID: 30097692 DOI: 10.1007/s00018-018-2892-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
51 Sandhu P, Haque M, Humphries-Bickley T, Ravi S, Song J. Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies. Front Immunol 2017;8:436. [PMID: 28450868 DOI: 10.3389/fimmu.2017.00436] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
52 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 1014] [Article Influence: 153.7] [Reference Citation Analysis]
53 Cheng D, Han B, Zhang W, Wu W. Clinical effects of NTCP-inhibitor myrcludex B. J Viral Hepat 2021;28:852-8. [PMID: 33599010 DOI: 10.1111/jvh.13490] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Su TH, Liu CJ. Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives. Gut Liver 2017;11:590-603. [PMID: 28494575 DOI: 10.5009/gnl16215] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
55 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel) 2021;14:417. [PMID: 34062711 DOI: 10.3390/ph14050417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Abdullah AA, Lee YK, Chin SP, Lim SK, Lee VS, Othman R, Othman S, Rahman NA, Yusof R, Heh CH. Discovery of Dengue Virus Inhibitors. Curr Med Chem 2020;27:4945-5036. [PMID: 30514185 DOI: 10.2174/0929867326666181204155336] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Debing Y, Neyts J. Antiviral strategies for hepatitis E virus. Antiviral Res 2014;102:106-18. [PMID: 24374149 DOI: 10.1016/j.antiviral.2013.12.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
58 Yang N, Bertoletti A. Advances in therapeutics for chronic hepatitis B. Hepatol Int 2016;10:277-85. [PMID: 26363922 DOI: 10.1007/s12072-015-9661-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
59 Verrier ER, Colpitts CC, Sureau C, Baumert TF. Hepatitis B virus receptors and molecular drug targets. Hepatol Int 2016;10:567-73. [DOI: 10.1007/s12072-016-9718-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
60 Gilman C, Heller T, Koh C. Chronic hepatitis delta: A state-of-the-art review and new therapies. World J Gastroenterol 2019; 25(32): 4580-4597 [PMID: 31528088 DOI: 10.3748/wjg.v25.i32.4580] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
61 Kapoor R, Kottilil S. Strategies to eliminate HBV infection. Future Virol 2014;9:565-85. [PMID: 25309617 DOI: 10.2217/fvl.14.36] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
62 Rumlová M, Ruml T. In vitro methods for testing antiviral drugs. Biotechnol Adv 2018;36:557-76. [PMID: 29292156 DOI: 10.1016/j.biotechadv.2017.12.016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
63 Li F, Cheng L, Murphy CM, Reszka-Blanco NJ, Wu Y, Chi L, Hu J, Su L. Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs. Sci Rep 2016;6:36483. [PMID: 27819342 DOI: 10.1038/srep36483] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
64 Sagnelli C, Sagnelli E, Russo A, Pisaturo M, Occhiello L, Coppola N. HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges. Life (Basel) 2021;11:169. [PMID: 33671730 DOI: 10.3390/life11020169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Wendt F, Milani ES, Wollscheid B. Elucidation of host-virus surfaceome interactions using spatial proteotyping. Adv Virus Res 2021;109:105-34. [PMID: 33934825 DOI: 10.1016/bs.aivir.2021.03.002] [Reference Citation Analysis]
66 Wilson EM, Tang L, Kottilil S. Eradication Strategies for Chronic Hepatitis B Infection. Clin Infect Dis 2016;62 Suppl 4:S318-25. [PMID: 27190322 DOI: 10.1093/cid/ciw044] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
67 Xia Y, Cheng X, Blossey CK, Wisskirchen K, Esser K, Protzer U. Secreted Interferon-Inducible Factors Restrict Hepatitis B and C Virus Entry In Vitro. J Immunol Res. 2017;2017:4828936. [PMID: 28367455 DOI: 10.1155/2017/4828936] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
68 Tu T, Urban S. Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections. Current Opinion in Virology 2018;30:68-79. [DOI: 10.1016/j.coviro.2018.04.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
69 Nosaka T, Naito T, Murata Y, Matsuda H, Ohtani M, Hiramatsu K, Nishizawa T, Okamoto H, Nakamoto Y. Regulatory function of interferon-inducible 44-like for hepatitis B virus covalently closed circular DNA in primary human hepatocytes. Hepatol Res 2021. [PMID: 34697871 DOI: 10.1111/hepr.13722] [Reference Citation Analysis]
70 Takizawa N, Yamasaki M. Current landscape and future prospects of antiviral drugs derived from microbial products. J Antibiot (Tokyo) 2017. [PMID: 29018267 DOI: 10.1038/ja.2017.115] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
71 Ko C, Chakraborty A, Chou WM, Hasreiter J, Wettengel JM, Stadler D, Bester R, Asen T, Zhang K, Wisskirchen K, McKeating JA, Ryu WS, Protzer U. Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels. J Hepatol. 2018;69:1231-1241. [PMID: 30142426 DOI: 10.1016/j.jhep.2018.08.012] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 18.3] [Reference Citation Analysis]
72 Leoni MC, Ustianowski A, Farooq H, Arends JE. HIV, HCV and HBV: A Review of Parallels and Differences. Infect Dis Ther 2018;7:407-19. [PMID: 30182282 DOI: 10.1007/s40121-018-0210-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
73 Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H; HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 2014;60:87-97. [PMID: 24585488 DOI: 10.1002/hep.27102] [Cited by in Crossref: 149] [Cited by in F6Publishing: 119] [Article Influence: 18.6] [Reference Citation Analysis]
74 Ezzikouri S, Ozawa M, Kohara M, Elmdaghri N, Benjelloun S, Tsukiyama-Kohara K. Recent insights into hepatitis B virus-host interactions. J Med Virol 2014;86:925-32. [PMID: 24604126 DOI: 10.1002/jmv.23916] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
75 Allweiss L, Dandri M. Experimental in vitro and in vivo models for the study of human hepatitis B virus infection. J Hepatol. 2016;64:S17-S31. [PMID: 27084033 DOI: 10.1016/j.jhep.2016.02.012] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 14.4] [Reference Citation Analysis]
76 Ismail NA, Jusoh SA. Molecular Docking and Molecular Dynamics Simulation Studies to Predict Flavonoid Binding on the Surface of DENV2 E Protein. Interdiscip Sci 2017;9:499-511. [PMID: 26969331 DOI: 10.1007/s12539-016-0157-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
77 Tang CM, Yau TO, Yu J. Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments. World J Gastroenterol 2014; 20(20): 6262-6278 [PMID: 24876747 DOI: 10.3748/wjg.v20.i20.6262] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 82] [Article Influence: 10.6] [Reference Citation Analysis]
78 Petersen J, Thompson AJ, Levrero M. Aiming for cure in HBV and HDV infection. J Hepatol 2016;65:835-48. [PMID: 27270043 DOI: 10.1016/j.jhep.2016.05.043] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
79 Buchmann B, Döhner K, Schirdewahn T, Sodeik B, Manns MP, Wedemeyer H, Ciesek S, von Hahn T. A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection. Antiviral Res 2017;141:116-23. [PMID: 28223128 DOI: 10.1016/j.antiviral.2017.02.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
80 Tu T, Zhang H, Urban S. Hepatitis B Virus DNA Integration: In Vitro Models for Investigating Viral Pathogenesis and Persistence. Viruses 2021;13:180. [PMID: 33530322 DOI: 10.3390/v13020180] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
81 Bahcecioglu IH, Sahin A. Treatment of Delta Hepatitis: Today and in the Future - A review. Infectious Diseases 2017;49:241-50. [DOI: 10.1080/23744235.2016.1271998] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
82 Asselah T, Loureiro D, Boyer N, Mansouri A. Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure. The Lancet Gastroenterology & Hepatology 2019;4:883-92. [DOI: 10.1016/s2468-1253(19)30190-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
83 Ye X, Zhou M, He Y, Wan Y, Bai W, Tao S, Ren Y, Zhang X, Xu J, Liu J, Zhang J, Hu K, Xie Y. Efficient Inhibition of Hepatitis B Virus Infection by a preS1-binding Peptide. Sci Rep 2016;6:29391. [PMID: 27384014 DOI: 10.1038/srep29391] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
84 Giersch K, Allweiss L, Volz T, Dandri M, Lütgehetmann M. Serum HBV pgRNA as a clinical marker for cccDNA activity. Journal of Hepatology 2017;66:460-2. [DOI: 10.1016/j.jhep.2016.09.028] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 14.6] [Reference Citation Analysis]
85 Hu J, Lin YY, Chen PJ, Watashi K, Wakita T. Cell and Animal Models for Studying Hepatitis B Virus Infection and Drug Development. Gastroenterology 2019;156:338-54. [PMID: 30243619 DOI: 10.1053/j.gastro.2018.06.093] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
86 Boucle S, Bassit L, Ehteshami M, Schinazi RF. Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities. Clin Liver Dis 2016;20:737-49. [PMID: 27742011 DOI: 10.1016/j.cld.2016.07.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
87 Zhang Z, Urban S. Interplay between Hepatitis D Virus and the Interferon Response. Viruses 2020;12:E1334. [PMID: 33233762 DOI: 10.3390/v12111334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
88 Verrier ER, Colpitts CC, Bach C, Heydmann L, Zona L, Xiao F, Thumann C, Crouchet E, Gaudin R, Sureau C, Cosset FL, McKeating JA, Pessaux P, Hoshida Y, Schuster C, Zeisel MB, Baumert TF. Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes. Cell Rep 2016;17:1357-68. [PMID: 27783949 DOI: 10.1016/j.celrep.2016.09.084] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
89 Schinazi RF, Ehteshami M, Bassit L, Asselah T. Towards HBV curative therapies. Liver Int 2018;38 Suppl 1:102-14. [PMID: 29427479 DOI: 10.1111/liv.13656] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 12.7] [Reference Citation Analysis]
90 Kang L, Pan J, Wu J, Hu J, Sun Q, Tang J. Anti-HBV Drugs: Progress, Unmet Needs, and New Hope. Viruses. 2015;7:4960-4977. [PMID: 26389937 DOI: 10.3390/v7092854] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
91 Tu T, Budzinska MA, Vondran FWR, Shackel NA, Urban S. Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an In Vitro Infection Model via Sodium Taurocholate Cotransporting Polypeptide-Dependent Uptake of Enveloped Virus Particles. J Virol 2018;92:e02007-17. [PMID: 29437961 DOI: 10.1128/JVI.02007-17] [Cited by in Crossref: 63] [Cited by in F6Publishing: 41] [Article Influence: 15.8] [Reference Citation Analysis]
92 Yuan L, Liu X, Zhang L, Li X, Zhang Y, Wu K, Chen Y, Cao J, Hou W, Zhang J, Zhu H, Yuan Q, Tang Q, Cheng T, Xia N. A Chimeric Humanized Mouse Model by Engrafting the Human Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cell for the Chronic Hepatitis B Virus Infection. Front Microbiol 2018;9:908. [PMID: 29867819 DOI: 10.3389/fmicb.2018.00908] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
93 Krause A, Haberkorn U, Mier W. Strategies for the treatment of HBV/HDV. Eur J Pharmacol. 2018;833:379-391. [PMID: 29935174 DOI: 10.1016/j.ejphar.2018.06.030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
94 Chulanov VP, Zueva AP, Kostyushev DS, Brezgin SA, Volchkova EV, Maleyev VV. [Hepatitis C can be cured: will hepatitis B become next?]. Ter Arkh 2017;89:4-13. [PMID: 29260740 DOI: 10.17116/terarkh201789114-13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
95 Zhang Z, Urban S. New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies. Journal of Hepatology 2021;74:686-99. [DOI: 10.1016/j.jhep.2020.11.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
96 Baumert TF, Meredith L, Ni Y, Felmlee DJ, McKeating JA, Urban S. Entry of hepatitis B and C viruses - recent progress and future impact. Curr Opin Virol 2014;4:58-65. [PMID: 24418809 DOI: 10.1016/j.coviro.2013.12.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
97 Alonso S, Guerra AR, Carreira L, Ferrer JÁ, Gutiérrez ML, Fernandez-Rodriguez CM. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon? BMC Gastroenterol 2017;17:168. [PMID: 29268704 DOI: 10.1186/s12876-017-0726-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
98 Allweiss L, Dandri M. The Role of cccDNA in HBV Maintenance. Viruses. 2017;9:156. [PMID: 28635668 DOI: 10.3390/v9060156] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 12.6] [Reference Citation Analysis]
99 Venkatakrishnan B, Zlotnick A. The Structural Biology of Hepatitis B Virus: Form and Function. Annu Rev Virol. 2016;3:429-451. [PMID: 27482896 DOI: 10.1146/annurev-virology-110615-042238] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 11.8] [Reference Citation Analysis]
100 Serigado JM, Izzy M, Kalia H. Novel therapies and potential therapeutic targets in the management of chronic hepatitis B. Eur J Gastroenterol Hepatol 2017;29:987-93. [PMID: 28538269 DOI: 10.1097/MEG.0000000000000911] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
101 Pan J, Tong S, Kang L, Tang J. New anti-hepatitis B virus drugs under development and evaluation: . Current Opinion in Infectious Diseases 2016;29:632-8. [DOI: 10.1097/qco.0000000000000318] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
102 Schinazi RF, Asselah T. From HCV To HBV Cure. Liver Int 2017;37 Suppl 1:73-80. [PMID: 28052627 DOI: 10.1111/liv.13324] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
103 Allweiss L, Giersch K, Pirosu A, Volz T, Muench RC, Beran RK, Urban S, Javanbakht H, Fletcher SP, Lütgehetmann M, Dandri M. Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo. Gut 2021:gutjnl-2020-322571. [PMID: 33509930 DOI: 10.1136/gutjnl-2020-322571] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
104 Dong J, Ying J, Qiu X, Lu Y, Zhang M. Advanced Strategies for Eliminating the cccDNA of HBV. Dig Dis Sci 2018;63:7-15. [PMID: 29159681 DOI: 10.1007/s10620-017-4842-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
105 Al-Azzam S, Ding Y, Liu J, Pandya P, Ting JP, Afshar S. Peptides to combat viral infectious diseases. Peptides 2020;134:170402. [PMID: 32889022 DOI: 10.1016/j.peptides.2020.170402] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
106 Jia H, Song Y, Yu J, Zhan P, Rai D, Liang X, Ma C, Liu X. Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors. European Journal of Medicinal Chemistry 2017;136:144-53. [DOI: 10.1016/j.ejmech.2017.04.048] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
107 Uchida T, Imamura M, Hayes CN, Hiraga N, Kan H, Tsuge M, Abe-Chayama H, Zhang Y, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice. Antimicrob Agents Chemother 2017;61:e00725-17. [PMID: 28696237 DOI: 10.1128/AAC.00725-17] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
108 Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology. 2014;147:48-64. [PMID: 24768844 DOI: 10.1053/j.gastro.2014.04.030] [Cited by in Crossref: 198] [Cited by in F6Publishing: 171] [Article Influence: 24.8] [Reference Citation Analysis]
109 Uhl P, Helm F, Hofhaus G, Brings S, Kaufman C, Leotta K, Urban S, Haberkorn U, Mier W, Fricker G. A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B. European Journal of Pharmaceutics and Biopharmaceutics 2016;103:159-66. [DOI: 10.1016/j.ejpb.2016.03.031] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
110 Giersch K, Dandri M. Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte. J Clin Transl Hepatol. 2015;3:220-229. [PMID: 26623269 DOI: 10.14218/jcth.2015.00018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
111 Rybicka M, Woziwodzka A, Romanowski T, Sznarkowska A, Stalke P, Dręczewski M, Bielawski KP. Host genetic background affects the course of infection and treatment response in patients with chronic hepatitis B. J Clin Virol 2019;120:1-5. [PMID: 31505315 DOI: 10.1016/j.jcv.2019.09.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
112 Moyo B, Bloom K, Scott T, Ely A, Arbuthnot P. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus. Virus Res 2018;244:311-20. [PMID: 28087399 DOI: 10.1016/j.virusres.2017.01.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
113 Maepa MB, Bloom K, Ely A, Arbuthnot P. Hepatitis B virus: promising drug targets and therapeutic implications. Expert Opin Ther Targets 2021;25:451-66. [PMID: 33843412 DOI: 10.1080/14728222.2021.1915990] [Reference Citation Analysis]
114 Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel M, Autran B, Cosset F, Strick-marchand H, Trépo C, Kao J, Carrat F, Lacombe K, Schinazi RF, Barré-sinoussi F, Delfraissy J, Zoulim F. Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure. Gut 2015;64:1314-26. [DOI: 10.1136/gutjnl-2014-308943] [Cited by in Crossref: 186] [Cited by in F6Publishing: 178] [Article Influence: 26.6] [Reference Citation Analysis]
115 Maiwall R, Kumar M. Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation. J Clin Transl Hepatol 2016;4:54-65. [PMID: 27047773 DOI: 10.14218/JCTH.2015.00041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
116 Wang W, Smith N, Makarov E, Sun Y, Gebhart CL, Ganesan M, Osna NA, Gendelman HE, Edagwa BJ, Poluektova LY. A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice. Nanomedicine 2020;28:102185. [PMID: 32217146 DOI: 10.1016/j.nano.2020.102185] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
117 Rizzetto M, Niro GA. Myrcludex B, a novel therapy for chronic hepatitis D? Journal of Hepatology 2016;65:465-6. [DOI: 10.1016/j.jhep.2016.06.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
118 Giersch K, Bhadra OD, Volz T, Allweiss L, Riecken K, Fehse B, Lohse AW, Petersen J, Sureau C, Urban S, Dandri M, Lütgehetmann M. Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo. Gut 2019;68:150-7. [PMID: 29217749 DOI: 10.1136/gutjnl-2017-314713] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
119 Dey D, Banerjee M. Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis. J Clin Transl Hepatol 2016;4:248-57. [PMID: 27777893 DOI: 10.14218/JCTH.2016.00025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
120 Revill P, Locarnini S. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA). Current Opinion in Pharmacology 2016;30:144-50. [DOI: 10.1016/j.coph.2016.08.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
121 Bengsch B, Chang KM. Evolution in Our Understanding of Hepatitis B Virus Virology and Immunology. Clin Liver Dis 2016;20:629-44. [PMID: 27742004 DOI: 10.1016/j.cld.2016.06.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
122 Kremsdorf D, Strick-Marchand H. Modeling hepatitis virus infections and treatment strategies in humanized mice. Curr Opin Virol 2017;25:119-25. [PMID: 28858692 DOI: 10.1016/j.coviro.2017.07.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
123 Brahmania M, Feld J, Arif A, Janssen HL. New therapeutic agents for chronic hepatitis B. Lancet Infect Dis 2016;16:e10-21. [PMID: 26795693 DOI: 10.1016/S1473-3099(15)00436-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
124 Lin CL, Yang HC, Kao JH. Hepatitis B virus: new therapeutic perspectives. Liver Int. 2016;36 Suppl 1:85-92. [PMID: 26725903 DOI: 10.1111/liv.13003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
125 Coffin CS, Lee SS. New paradigms in hepatitis B management: only diamonds are forever. Br Med Bull 2015;116:79-91. [PMID: 26377741 DOI: 10.1093/bmb/ldv039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
126 Liu SK, Seto W, Lai C, Yuen M. Hepatitis B: treatment choice and monitoring for response and resistance. Expert Review of Gastroenterology & Hepatology 2016;10:697-707. [DOI: 10.1586/17474124.2016.1145547] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
127 Morikawa K, Suda G, Sakamoto N. Viral life cycle of hepatitis B virus: Host factors and druggable targets. Hepatol Res 2016;46:871-7. [PMID: 26776362 DOI: 10.1111/hepr.12650] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
128 Ghany MG, Block TM. Disease Pathways and Mechanisms of Potential Drug Targets. Clin Liver Dis (Hoboken) 2018;12:12-8. [PMID: 30988903 DOI: 10.1002/cld.735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
129 Mueller H, Wildum S, Luangsay S, Walther J, Lopez A, Tropberger P, Ottaviani G, Lu W, Parrott NJ, Zhang JD, Schmucki R, Racek T, Hoflack J, Kueng E, Point F, Zhou X, Steiner G, Lütgehetmann M, Rapp G, Volz T, Dandri M, Yang S, Young JA, Javanbakht H. A novel orally available small molecule that inhibits hepatitis B virus expression. Journal of Hepatology 2018;68:412-20. [DOI: 10.1016/j.jhep.2017.10.014] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 15.8] [Reference Citation Analysis]
130 Alfaiate D, Dény P, Durantel D. Hepatitis delta virus: From biological and medical aspects to current and investigational therapeutic options. Antiviral Research 2015;122:112-29. [DOI: 10.1016/j.antiviral.2015.08.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
131 Bloom K, Maepa MB, Ely A, Arbuthnot P. Gene Therapy for Chronic HBV-Can We Eliminate cccDNA? Genes (Basel) 2018;9:E207. [PMID: 29649127 DOI: 10.3390/genes9040207] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
132 Kang C, Syed YY. Bulevirtide: First Approval. Drugs. 2020;80:1601-1605. [PMID: 32926353 DOI: 10.1007/s40265-020-01400-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
133 Manzoor S, Saalim M, Imran M, Resham S, Ashraf J. Hepatitis B virus therapy: What’s the future holding for us? World J Gastroenterol 2015; 21(44): 12558-12575 [PMID: 26640332 DOI: 10.3748/wjg.v21.i44.12558] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
134 Dandri M, Petersen J. cccDNA Maintenance in Chronic Hepatitis B - Targeting the Matrix of Viral Replication. Infect Drug Resist 2020;13:3873-86. [PMID: 33149632 DOI: 10.2147/IDR.S240472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
135 Kushner T, Serper M, Kaplan DE. Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes. J Hepatol. 2015;63:586-592. [PMID: 25962883 DOI: 10.1016/j.jhep.2015.04.025] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 8.9] [Reference Citation Analysis]
136 Sintusek P, Thanapirom K, Komolmit P, Poovorawan Y. Eliminating viral hepatitis in children after liver transplants: How to reach the goal by 2030. World J Gastroenterol 2022; 28(3): 290-309 [DOI: 10.3748/wjg.v28.i3.290] [Reference Citation Analysis]
137 Chen S, Yu X, Guo D. CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy. Viruses 2018;10:E40. [PMID: 29337866 DOI: 10.3390/v10010040] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
138 Lewandowska M, Piekarska A. New directions in hepatitis B therapy research. Clin Exp Hepatol 2017;3:119-26. [PMID: 29062901 DOI: 10.5114/ceh.2017.68831] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
139 Whitacre DC, Peters CJ, Sureau C, Nio K, Li F, Su L, Jones JE, Isogawa M, Sallberg M, Frelin L, Peterson DL, Milich DR. Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance. Hum Vaccin Immunother 2020;16:251-68. [PMID: 31809638 DOI: 10.1080/21645515.2019.1689745] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
140 Zhang X, Zhang Q, Peng Q, Zhou J, Liao L, Sun X, Zhang L, Gong T. Hepatitis B virus preS1-derived lipopeptide functionalized liposomes for targeting of hepatic cells. Biomaterials 2014;35:6130-41. [DOI: 10.1016/j.biomaterials.2014.04.037] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
141 Tsukamoto Y, Ikeda S, Uwai K, Taguchi R, Chayama K, Sakaguchi T, Narita R, Yao WL, Takeuchi F, Otakaki Y, Watashi K, Wakita T, Kato H, Fujita T. Rosmarinic acid is a novel inhibitor for Hepatitis B virus replication targeting viral epsilon RNA-polymerase interaction. PLoS One 2018;13:e0197664. [PMID: 29782545 DOI: 10.1371/journal.pone.0197664] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
142 Nicolini LA, Orsi A, Tatarelli P, Viscoli C, Icardi G, Sticchi L. A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals. Int J Environ Res Public Health 2019;16:E3307. [PMID: 31505743 DOI: 10.3390/ijerph16183307] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
143 De La Guardia C, Lleonart R. Progress in the identification of dengue virus entry/fusion inhibitors. Biomed Res Int 2014;2014:825039. [PMID: 25157370 DOI: 10.1155/2014/825039] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
144 Asselah T, Loureiro D, Tout I, Castelnau C, Boyer N, Marcellin P, Mansouri A. Future treatments for hepatitis delta virus infection. Liver Int. 2020;40 Suppl 1:54-60. [PMID: 32077603 DOI: 10.1111/liv.14356] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
145 Dandri M, Petersen J. Animal models of HBV infection. Best Pract Res Clin Gastroenterol 2017;31:273-9. [PMID: 28774409 DOI: 10.1016/j.bpg.2017.04.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
146 Mohebbi A, Lorestani N, Tahamtan A, Kargar NL, Tabarraei A. An Overview of Hepatitis B Virus Surface Antigen Secretion Inhibitors. Front Microbiol 2018;9:662. [PMID: 29675010 DOI: 10.3389/fmicb.2018.00662] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
147 Blank A, Markert C, Hohmann N, Carls A, Mikus G, Lehr T, Alexandrov A, Haag M, Schwab M, Urban S, Haefeli WE. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol. 2016;65:483-489. [PMID: 27132172 DOI: 10.1016/j.jhep.2016.04.013] [Cited by in Crossref: 112] [Cited by in F6Publishing: 101] [Article Influence: 18.7] [Reference Citation Analysis]
148 Chauhan R, Lingala S, Gadiparthi C, Lahiri N, Mohanty SR, Wu J, Michalak TI, Satapathy SK. Reactivation of hepatitis B after liver transplantation: Current knowledge, molecular mechanisms and implications in management. World J Hepatol 2018; 10(3): 352-370 [PMID: 29599899 DOI: 10.4254/wjh.v10.i3.352] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
149 Allweiss L, Volz T, Giersch K, Kah J, Raffa G, Petersen J, Lohse AW, Beninati C, Pollicino T, Urban S, Lütgehetmann M, Dandri M. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut 2018;67:542-52. [PMID: 28428345 DOI: 10.1136/gutjnl-2016-312162] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 15.8] [Reference Citation Analysis]
150 Dandri M, Bertoletti A, Lütgehetmann M. Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition. Semin Immunopathol 2021. [PMID: 34019142 DOI: 10.1007/s00281-021-00864-x] [Reference Citation Analysis]
151 Hu Y, Zhu W, Tang G, Mayweg AV, Yang G, Wu JZ, Shen HC. Novel Therapeutics in Discovery and Development for Treatment of Chronic HBV Infection. Elsevier; 2013. pp. 265-81. [DOI: 10.1016/b978-0-12-417150-3.00017-x] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
152 Bian Y, Zhang Z, Sun Z, Zhao J, Zhu D, Wang Y, Fu S, Guo J, Liu L, Su L, Wang FS, Fu YX, Peng H. Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice. Hepatology 2017;66:1067-82. [PMID: 28445927 DOI: 10.1002/hep.29239] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
153 Singh L, Indermun S, Govender M, Kumar P, du Toit LC, Choonara YE, Pillay V. Drug Delivery Strategies for Antivirals against Hepatitis B Virus. Viruses 2018;10:E267. [PMID: 29772748 DOI: 10.3390/v10050267] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
154 Mason WS. Animal models and the molecular biology of hepadnavirus infection. Cold Spring Harb Perspect Med. 2015;5. [PMID: 25833941 DOI: 10.1101/cshperspect.a021352] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
155 Ely A, Singh P, Smith TS, Arbuthnot P. In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection. Adv Drug Deliv Rev. 2021;168:134-146. [PMID: 32485207 DOI: 10.1016/j.addr.2020.05.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
156 Oehler N, Volz T, Bhadra OD, Kah J, Allweiss L, Giersch K, Bierwolf J, Riecken K, Pollok JM, Lohse AW. Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism. Hepatology. 2014;60:1483-1493. [PMID: 24711282 DOI: 10.1002/hep.27159] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 10.4] [Reference Citation Analysis]
157 Ward H, Tang L, Poonia B, Kottilil S. Treatment of hepatitis B virus: an update. Future Microbiol. 2016;11:1581-1597. [PMID: 27855500 DOI: 10.2217/fmb-2016-0128] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
158 Xia Y, Liang TJ. Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection. Gastroenterology 2019;156:311-24. [PMID: 30243618 DOI: 10.1053/j.gastro.2018.07.057] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
159 Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J. 2013;10:239. [PMID: 23870415 DOI: 10.1186/1743-422x-10-239] [Cited by in Crossref: 152] [Cited by in F6Publishing: 74] [Article Influence: 16.9] [Reference Citation Analysis]
160 Allweiss L, Lütgehetmann M, Dandri M. Immunofluorescent Staining for the Detection of the Hepatitis B Core Antigen in Frozen Liver Sections of Human Liver Chimeric Mice. Methods Mol Biol 2017;1540:135-42. [PMID: 27975313 DOI: 10.1007/978-1-4939-6700-1_11] [Reference Citation Analysis]
161 Trauner M, Fuchs CD, Halilbasic E, Paumgartner G. New therapeutic concepts in bile acid transport and signaling for management of cholestasis. Hepatology 2017;65:1393-404. [PMID: 27997980 DOI: 10.1002/hep.28991] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 18.8] [Reference Citation Analysis]
162 Revill PA, Lewin SR. Editorial: Strategies and barriers for hepatitis B cure: implications for HIV. Curr Opin HIV AIDS 2020;15:151-6. [PMID: 32229770 DOI: 10.1097/COH.0000000000000620] [Reference Citation Analysis]
163 Shih C, Chou S, Yang C, Huang J, Choijilsuren G, Jhou R. Control and Eradication Strategies of Hepatitis B Virus. Trends in Microbiology 2016;24:739-49. [DOI: 10.1016/j.tim.2016.05.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
164 Li BS, Sun DX. Role of covalently closed circular DNA in treatment of chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2016; 24(12): 1824-1831 [DOI: 10.11569/wcjd.v24.i12.1824] [Reference Citation Analysis]
165 Dandri M, Lütgehetmann M. Mouse models of hepatitis B and delta virus infection. J Immunol Methods 2014;410:39-49. [PMID: 24631647 DOI: 10.1016/j.jim.2014.03.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
166 Huang JT, Yang Y, Hu YM, Liu XH, Liao MY, Morgan R, Yuan EF, Li X, Liu SM. A Highly Sensitive and Robust Method for Hepatitis B Virus Covalently Closed Circular DNA Detection in Single Cells and Serum. J Mol Diagn. 2018;20:334-343. [PMID: 29656833 DOI: 10.1016/j.jmoldx.2018.01.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
167 Korolowicz KE, Suresh M, Li B, Huang X, Yon C, Kallakury BV, Lee KP, Park S, Kim YW, Menne S. Combination Treatment with the Vimentin-Targeting Antibody hzVSF and Tenofovir Suppresses Woodchuck Hepatitis Virus Infection in Woodchucks. Cells 2021;10:2321. [PMID: 34571970 DOI: 10.3390/cells10092321] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol 2021; 27(16): 1691-1715 [PMID: 33967551 DOI: 10.3748/wjg.v27.i16.1691] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
169 Kah J, Koh S, Volz T, Ceccarello E, Allweiss L, Lütgehetmann M, Bertoletti A, Dandri M. Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection. J Clin Invest 2017;127:3177-88. [PMID: 28737510 DOI: 10.1172/JCI93024] [Cited by in Crossref: 65] [Cited by in F6Publishing: 37] [Article Influence: 13.0] [Reference Citation Analysis]
170 Ito K. Difference between genotypes B and C in the decline and disappearance of hepatitis B surface antigen: Toward an era of direct-acting antiviral agents for hepatitis B virus. Hepatol Res 2019;49:1253-5. [PMID: 31820538 DOI: 10.1111/hepr.13456] [Reference Citation Analysis]
171 Ferdek PE, Jakubowska MA, Gerasimenko JV, Gerasimenko OV, Petersen OH. Bile acids induce necrosis in pancreatic stellate cells dependent on calcium entry and sodium-driven bile uptake. J Physiol 2016;594:6147-64. [PMID: 27406326 DOI: 10.1113/JP272774] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
172 König A, Yang J, Jo E, Park KHP, Kim H, Than TT, Song X, Qi X, Dai X, Park S, Shum D, Ryu WS, Kim JH, Yoon SK, Park JY, Ahn SH, Han KH, Gerlich WH, Windisch MP. Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells. J Hepatol 2019;71:289-300. [PMID: 31077792 DOI: 10.1016/j.jhep.2019.04.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
173 Dandri M, Petersen J. Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential. Clin Infect Dis 2016;62 Suppl 4:S281-8. [PMID: 27190317 DOI: 10.1093/cid/ciw023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
174 Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2016;2:163-186. [PMID: 28042609 DOI: 10.20517/2394-5079.2016.05] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 10.7] [Reference Citation Analysis]
175 Reinharz V, Ishida Y, Tsuge M, Durso-Cain K, Chung TL, Tateno C, Perelson AS, Uprichard SL, Chayama K, Dahari H. Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice. J Virol 2021;95:e0049220. [PMID: 33910953 DOI: 10.1128/JVI.00492-20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
176 Yuan L, Liu X, Zhang L, Zhang Y, Chen Y, Li X, Wu K, Cao J, Hou W, Que Y, Zhang J, Zhu H, Yuan Q, Tang Q, Cheng T, Xia N. Optimized HepaRG is a suitable cell source to generate the human liver chimeric mouse model for the chronic hepatitis B virus infection. Emerg Microbes Infect 2018;7:144. [PMID: 30097574 DOI: 10.1038/s41426-018-0143-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
177 Phyo WW, Soh AYS, Lim SG, Lee GH. Search for a cure for chronic hepatitis B infection: How close are we? World J Hepatol 2015; 7(9): 1272-1281 [PMID: 26019743 DOI: 10.4254/wjh.v7.i9.1272] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
178 Boettler T, Moradpour D, Thimme R, Zoulim F. Bridging basic science and clinical research - the EASL Monothematic Conference on Translational Research in Viral Hepatitis. J Hepatol. 2014;61:696-705. [PMID: 24845610 DOI: 10.1016/j.jhep.2014.05.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
179 Li FC, Li YK, Fan YC. Biomarkers for hepatitis B virus replication: an overview and a look to the future. Expert Rev Gastroenterol Hepatol 2020;14:1131-9. [PMID: 32887529 DOI: 10.1080/17474124.2020.1815530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Tan G, Song H, Xu F, Cheng G. When Hepatitis B Virus Meets Interferons. Front Microbiol 2018;9:1611. [PMID: 30072974 DOI: 10.3389/fmicb.2018.01611] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
181 Lim SP, Wang QY, Noble CG, Chen YL, Dong H, Zou B, Yokokawa F, Nilar S, Smith P, Beer D, Lescar J, Shi PY. Ten years of dengue drug discovery: progress and prospects. Antiviral Res 2013;100:500-19. [PMID: 24076358 DOI: 10.1016/j.antiviral.2013.09.013] [Cited by in Crossref: 239] [Cited by in F6Publishing: 211] [Article Influence: 26.6] [Reference Citation Analysis]
182 Thangamani L, Balasubramanian B, Easwaran M, Natarajan J, Pushparaj K, Meyyazhagan A, Piramanayagam S. GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics. Pharmacol Res 2021;173:105864. [PMID: 34474100 DOI: 10.1016/j.phrs.2021.105864] [Reference Citation Analysis]
183 Tang L, Zhao Q, Wu S, Cheng J, Chang J, Guo JT. The current status and future directions of hepatitis B antiviral drug discovery. Expert Opin Drug Discov 2017;12:5-15. [PMID: 27797587 DOI: 10.1080/17460441.2017.1255195] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
184 Tu W, Zheng J. Application of Humanized Mice in Immunological Research. Methods Mol Biol 2016;1371:157-76. [PMID: 26530800 DOI: 10.1007/978-1-4939-3139-2_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
185 Hwang JR, Park SG. Mouse models for hepatitis B virus research. Lab Anim Res 2018;34:85-91. [PMID: 30310404 DOI: 10.5625/lar.2018.34.3.85] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
186 Leng XJ, Yan XB. Status and development of anti-HBV drugs based on "HBF drug watch". Shijie Huaren Xiaohua Zazhi 2016; 24(15): 2336-2346 [DOI: 10.11569/wcjd.v24.i15.2336] [Reference Citation Analysis]
187 Spyrou E, Smith CI, Ghany MG. Hepatitis B: Current Status of Therapy and Future Therapies. Gastroenterol Clin North Am 2020;49:215-38. [PMID: 32389360 DOI: 10.1016/j.gtc.2020.01.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
188 Chauhan R, Li Q, Woodson ME, Gasonoo M, Meyers MJ, Tavis JE. Efficient Inhibition of Hepatitis B Virus (HBV) Replication and cccDNA Formation by HBV Ribonuclease H Inhibitors during Infection. Antimicrob Agents Chemother 2021;65:e0146021. [PMID: 34516242 DOI: 10.1128/AAC.01460-21] [Reference Citation Analysis]
189 Revill P, Locarnini S. The Basis for Antiviral Therapy: Drug Targets, Cross-Resistance, and Novel Small Molecule Inhibitors. In: Liaw Y, Zoulim F, editors. Hepatitis B Virus in Human Diseases. Cham: Springer International Publishing; 2016. pp. 303-24. [DOI: 10.1007/978-3-319-22330-8_14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
190 Lempp FA, Schlund F, Rieble L, Nussbaum L, Link C, Zhang Z, Ni Y, Urban S. Recapitulation of HDV infection in a fully permissive hepatoma cell line allows efficient drug evaluation. Nat Commun 2019;10:2265. [PMID: 31118422 DOI: 10.1038/s41467-019-10211-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
191 Skupsky J, Hu K. Current hepatitis B treatment guidelines and future research directions. Front Med 2014;8:145-57. [DOI: 10.1007/s11684-014-0335-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
192 Lin CL, Kao JH. Review article: novel therapies for hepatitis B virus cure - advances and perspectives. Aliment Pharmacol Ther. 2016;44:213-222. [PMID: 27302653 DOI: 10.1111/apt.13694] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
193 Defresne F, Sokal E. Chronic hepatitis B in children: therapeutic challenges and perspectives. J Gastroenterol Hepatol. 2016; Epub ahead of print. [PMID: 27262164 DOI: 10.1111/jgh.13459] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
194 Schlicksup CJ, Wang JC, Francis S, Venkatakrishnan B, Turner WW, VanNieuwenhze M, Zlotnick A. Hepatitis B virus core protein allosteric modulators can distort and disrupt intact capsids. Elife 2018;7:e31473. [PMID: 29377794 DOI: 10.7554/eLife.31473] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 11.5] [Reference Citation Analysis]
195 Liu Y, Ruan H, Li Y, Sun G, Liu X, He W, Mao F, He M, Yan L, Zhong G, Yan H, Li W, Zhang Z. Potent and Specific Inhibition of NTCP-Mediated HBV/HDV Infection and Substrate Transporting by a Novel, Oral-Available Cyclosporine A Analogue. J Med Chem 2021;64:543-65. [PMID: 33369415 DOI: 10.1021/acs.jmedchem.0c01484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
196 Wisskirchen K, Kah J, Malo A, Asen T, Volz T, Allweiss L, Wettengel JM, Lütgehetmann M, Urban S, Bauer T, Dandri M, Protzer U. T cell receptor grafting allows virological control of Hepatitis B virus infection. J Clin Invest 2019;129:2932-45. [PMID: 31039136 DOI: 10.1172/JCI120228] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 9.7] [Reference Citation Analysis]
197 Loureiro D, Castelnau C, Tout I, Boyer N, Narguet S, Menasria Benazzouz S, Louis Z, Pons-Kerjean N, Giuly N, Marcellin P, Mansouri A, Asselah T. New therapies for hepatitis delta virus infection. Liver Int 2021;41 Suppl 1:30-7. [PMID: 34155804 DOI: 10.1111/liv.14838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Fofana I, Jilg N, Chung RT, Baumert TF. Entry inhibitors and future treatment of hepatitis C. Antiviral Res 2014;104:136-42. [PMID: 24525381 DOI: 10.1016/j.antiviral.2014.02.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
199 Zhao K, Liu S, Chen Y, Yao Y, Zhou M, Yuan Y, Wang Y, Pei R, Chen J, Hu X, Zhou Y, Zhao H, Lu M, Wu C, Chen X. Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B. Emerg Microbes Infect 2018;7:186. [PMID: 30459339 DOI: 10.1038/s41426-018-0189-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
200 Meredith LW, Hu K, Cheng X, Howard CR, Baumert TF, Balfe P, van de Graaf KF, Protzer U, McKeating JA. Lentiviral hepatitis B pseudotype entry requires sodium taurocholate co-transporting polypeptide and additional hepatocyte-specific factors. J Gen Virol 2016;97:121-7. [PMID: 26474824 DOI: 10.1099/jgv.0.000317] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
201 Baumert TF, Verrier ER, Nassal M, Chung RT, Zeisel MB. Host-targeting agents for treatment of hepatitis B virus infection. Curr Opin Virol. 2015;14:41-46. [PMID: 26262886 DOI: 10.1016/j.coviro.2015.07.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
202 Arends JE, Lieveld FI, Ahmad S, Ustianowski A. New Viral and Immunological Targets for Hepatitis B Treatment and Cure: A Review. Infect Dis Ther 2017;6:461-76. [PMID: 29071665 DOI: 10.1007/s40121-017-0173-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
203 Chen J, Wu M, Liu K, Zhang W, Li Y, Zhou X, Bai L, Yuan Z. New insights into hepatitis B virus biology and implications for novel antiviral strategies. National Science Review 2015;2:296-313. [DOI: 10.1093/nsr/nwv044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
204 Zhang Z, Trippler M, Real CI, Werner M, Luo X, Schefczyk S, Kemper T, Anastasiou OE, Ladiges Y, Treckmann J, Paul A, Baba HA, Allweiss L, Dandri M, Gerken G, Wedemeyer H, Schlaak JF, Lu M, Broering R. Hepatitis B Virus Particles Activate Toll-Like Receptor 2 Signaling Initially Upon Infection of Primary Human Hepatocytes. Hepatology 2020;72:829-44. [PMID: 31925967 DOI: 10.1002/hep.31112] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
205 Wang YJ, Yang L, Zuo JP. Recent developments in antivirals against hepatitis B virus. Virus Res. 2016;213:205-213. [PMID: 26732483 DOI: 10.1016/j.virusres.2015.12.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]